Active substance
Insulin neutral
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ACTRAPID | 100 IU/ml | Solution · Subcutaneous use | 1 Vial | SAR 65.00 | Biological · Prescription | NOVO NORDISK | Valid |
| ACTRAPID HM PENFILL CARTRAGE | 100 IU/ml | Solution for injection in cartridge · Subcutaneous use | 5 Cartridge | SAR 62.65 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
| ACTRAPID NOVOLET 100 I.U | 100 IU/ml | Solution for injection · Subcutaneous use | 5 Cartridge | SAR 166.35 | Biological · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
| ACTRAPID PENFILL | 100 IU/ml | Suspension for injection · Subcutaneous use | 5 Cartridge | SAR 103.35 | Biological · Prescription | NOVO NORDISK | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ MALIGNANT HYPERTHERMIA; BRADYCARDIA; DIABETES MELLITUS TYPE 1; DIABETES MELLITUS TYPE 2
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.